Navigation Links
'Worm Therapy' Might Help Ease Colitis, Monkey Study Shows
Date:11/16/2012

By Alan Mozes
HealthDay Reporter

FRIDAY, Nov. 16 (HealthDay News) -- For people with Crohn's disease and colitis, relief might come in the form of swallowing microscopic parasitic pig worm eggs, according to a new animal study of that unsavory-sounding treatment.

In five young rhesus monkeys diagnosed with "idiopathic chronic diarrhea," worm treatment relieved their symptoms and resulted in a healthier gut and reduced inflammation of the large intestine, or colon.

Such worms -- or helminths -- typically have resided in the human intestinal tract, helping to keep it healthy. But in the world's most developed regions, the presence of these worms in the human body is fading. And autoimmune bowel disorders like Crohn's and colitis are on the rise.

"Helminths are parasites, and they are pathogenic," said study co-author P'ng Loke, an assistant professor of microbiology at NYU Langone Medical Center, in New York City. "So in much of the world we try to get rid of them, because when children that are malnourished have helminth infections it can cause severe health problems," Loke said.

"But in the industrialized world you have to think about things from a different perspective, because a lot of autoimmune diseases have increased really rapidly over the last 50 years, as our societies have become more developed," Loke explained. "And at the same time, while up until recently about 70 to 80 percent of people were colonized with helminths, complex changes to the environment, largely due to changes in eating habits, have drastically reduced this number."

In industrialized countries where helminth "infections" have dropped dramatically, inflammatory bowel disease has shot up and now affects about 1.4 million Americans.

While previous research has suggested that reintroducing helminths and other microbials back into these patients might help, exactly how these worms seem to work their intestinal magic was unclear. Until now.

"What we're talking about here are very carefully controlled and complex clinical trials in which the helminths we use are certified to be pathogen-free by the [U.S. Food and Drug Administration]," Loke said. "And what we're seeing is that these worms seem to act to restore the immune regulatory networks, which control the immune system, by restoring gut bacteria levels and stimulating mucus production."

The study appears in the November issue of PLoS Pathogens. The team included researchers from the University of California, San Francisco, the California National Primate Research Center in Davis, the University of Texas Southwestern Medical Center at Dallas, and New York University.

For the monkeys in the study, their diarrheal disease was considered similar to immune bowel disorders in humans, with symptoms such as progressive weight loss and dehydration. In primate research centers, the illness is one of the main causes of death among such monkeys.

Tissue sample analyses revealed that the previously impaired bacterial composition of the monkeys' intestinal walls had been restored to near healthy levels following helminth treatment. Four of the five monkeys showed clear signs of reduced diarrhea and weight gain as a result of the intervention.

So what is a Crohn's or colitis patient to make of all this?

"I would say that the FDA is looking at this approach as it would with any other drug, and so should the consumer," Loke said. "It's like a vaccine, or at least a live attenuated vaccine, in which you're immunizing yourself with a virus that doesn't harm you to get protection from a virus that does. And I'm sure at one point the idea of immunizing with a vaccine seemed kind of crazy. But now we understand that it's a critical part of achieving protection."

That thought is seconded by Dr. Edward Loftus, Jr., a professor of medicine and director of the inflammatory bowel disease interest group, at the Mayo Clinic in Rochester, Minn.

"I think the average layperson might find this horrifying," Loftus acknowledged. "But actually the average well-read [inflammatory bowel disease] patient would probably be very eager to explore this therapy, because a lot of patients are scared by our more conventional immuno-suppressive and biologic treatments, which carry a small risk of serious infections and other side effects," he pointed out.

"And this fascinating and kind of novel study suggests that these worms can help by significantly affecting the bacterial makeup of the colon," Loftus said. "For the large subset of patients who are looking for an alternative approach, this finding could be incredibly appealing."

Scientists note that research with animals -- monkeys in this case -- often fails to provide similar results in humans.

More information

To learn more about colitis, visit the U.S. National Library of Medicine.

SOURCES: P'ng Loke, Ph.D., assistant professor of microbiology, department of microbiology, NYU Langone Medical Center, New York City; Edward Loftus, Jr., M.D., professor of medicine, and director, inflammatory bowel disease interest group, division of gastroenterology and hepatology, Mayo Clinic, Rochester, Minn.; Nov. 15, 2012, PLOS Pathogens


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. GW Researcher receives grant to study parasitic worm role in bile duct cancer in Southeast Asia
2. Clinical trials for first-ever human hookworm vaccine advance
3. Global health researchers urge integrating de-worming into HIV care in Africa
4. Spaceflight may extend the lifespan of microscopic worm
5. Study shows large-scale genomic testing feasible, impacts therapy
6. Potential new technique for anticancer radiotherapy could provide alternative to brachytherapy
7. Cancer therapy -- Nanokey opens tumors to attack
8. Should hyperbaric oxygen therapy be used to treat combat-related mild traumatic brain injury?
9. Antiviral Therapy May Cut Recurrence of Hepatitis B-Linked Liver Cancer
10. Expensive arthritis treatment no better than steroid therapy
11. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Worm Therapy' Might Help Ease Colitis, Monkey Study Shows
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC ... of medical professionals throughout the country. The Guard was specifically designed to handle ... procedures, employee training, regulatory updates, and compliance coaching. , In addition to meeting ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Dr. Jessica Barron, ... practice is now accepting new dental patients and families in the North Metro Denver ... care services from cleanings to cosmetic dentistry, and all in the most relaxing environment. ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the ... ended December 31, 2015 on Monday, February 29, 2016 after the market closes. , ... the release at 4:30 PM ET. Investors interested in participating by phone are invited ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... development of a once-daily, oral therapy for the treatment ... Officer, Dr. Maya Halpern , has notified the Company ... Officer and from its Board of Directors effective as ... age. Allen Baharaff . Mr. Baharaff continued, ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... in the U.S. and Europe , announced ... laser at the upcoming 151 st Midwinter Meeting of ... #4815. The ST PRO is a full featured hard and ... the award winning, industry leading Lightwalker ATS. At an introductory price ... attractive to many dentists hesitating to incorporate lasers into their ...
Breaking Medicine Technology: